AAIPharma Services will soon be growing larger – as part of a bigger company.

The Wilmington-based provider of various pharmaceutical services says it is combining forces with Cambridge Major Laboratories, which is based in Germantown, Wis.

No financial terms were disclosed. Both companies are privately held. The deal was disclosed early Tuesday. 

”The merger of these two organizations will offer customers a reliable partner that can address the majority of their pharmaceutical development and manufacturing requirements,” said Patrick Walsh, CEO of AAIPharma, in a statement. “The combined organization will provide comprehensive services that include process chemistry, solid state chemistry, API manufacturing, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid and sterile), packaging, and stability services, all supported by robust project management.”

Cambridge Major Laboratories, or CML, focuses on pharmaceutical development and manufacturing.

AAIPharma provides pharmaceutical analytical testing, product development, and manufacturing services.

The deal is expected to close before the end of October.

“The basis for the merger was to start with the right building blocks – a merger of two equals: two highly respected, market-leading firms with proven expertise in API development, analytical chemistry, and finished dosage forms,” said Brian Scanlan, CML’s CEO, in announcing the deal. “We believe that we have a strong foundation to deliver superior customer-oriented solutions to expedite drug development and commercialization.”